MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma

Affiliations

• ¹ Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom.
• ² Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
• ³ Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA.